| C-07 Anyue Yin Anti-cancer treatment schedule optimization based on tumor dynamics modelling incorporating evolving resistance Monday 14:00-14:20 |
| C-08 Sreenath M Krishnan Multistate model for pharmacometric analyses of overall survival in anticancer treatments Monday 14:20-14:40 |
| C-09 René Bruno Operating characteristics of tumor growth inhibition-overall survival models to support early Phase Ib decisions: An evaluation in first-line metastatic non-small cell lung cancer patients treated with atezolizumab plus chemotherapy based on the Phase III study IMpower150 Monday 14:40-15:00 |
| D-05 Alexandra Lavalley-Morelle Individual dynamic predictions in joint analysis for nonlinear marker evolution and competing risk data: application on patients admitted in Intensive Care Unit for sepsis Tuesday 13:40-14:00 |
| D-10 David Busse Body composition and drug exposure in adipose tissue are key for antibiotic dose-individualisation in obese individuals Tuesday 14:50-15:10 |
| D-11 Jérémy Seurat Combination of in vivo phage therapy data with in silico model highlights key parameters for treatment efficacy Tuesday 15:10-15:30 |
| D-15 Marie Alexandre Dynamics of the humoral immune response to a two-dose heterologous vaccine regimen against Ebola virus. Tuesday 16:35-16:55 |
| D-16 João Abrantes Model-informed development of RG6102, an amyloid-targeting investigational drug with enhanced brain penetration properties Tuesday 16:55-17:15 |
